We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 1.31% | 6.20 | 5.52 | 7.00 | 6.20 | 6.20 | 6.20 | 84,000 | 14:20:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.71 | 12.48M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 16/11/2020 19:47 | .... I wouldn't put him in the top 5 | festario | |
| 16/11/2020 19:44 | What? When Donald Trump, Boris Johnson and Kim Jong Un still walk the Earth? | festario | |
| 16/11/2020 18:43 | Totally agree on safety this should not be key hold up , but the peer review would have been important and the data around Ph2 efficacy well thumbed ..there's then the nature and price of any arrangement all in the clouds of a pandemic.Let's see , I remain confident that SNG0001 will play an important roll in combatting CVD19 and other respiratory viral conditions ,the market cap is small relative to potential ..so the risk reward as it progresses looks good to me. Fingers crossed hey! | kooba | |
| 16/11/2020 18:36 | Kooba - yeah, except of course SNG has 16 years of safety data for 001 in a COPD context. If Marsden doesn't get his act together soon - like, by the end of the month - he risks going down as the muppet who fell into the biggest barrel of nipples in history and came out sucking his thumb. He'll be a laughing stock for the rest of his life. | sloppyjoe2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
